Docetaxel combined with trastuzumab is an active regimen in HER-2 3+ overexpressing and fluorescent in situ hybridization-positive metastatic breast cancer: A multi-institutional phase II trial

K. L. Tedesco, A. D. Thor, David H. Johnson, Y. Shyr, K. A. Blum, L. J. Goldstein, W. J. Gradishar, B. P. Nicholson, D. E. Merkel, D. Murrey, S. Edgerton, G. W. Sledge